OCGN EBITDA | OCUGEN, INC.

OCUGEN, INC. (OCGN) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$16.44M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$17.84M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$17.63M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$13.79M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2021-12-31 to 2022-12-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$16.44M	(m)	$1.49M	(m)	$21.00K*	-$12.20M*	(m)	$10.69M	(m)	(m)
2026-03-31	Reported	(m)	-$17.84M	(m)	$1.53M	(m)	$6.00K	-$21.79M	(m)	$11.26M	(m)	(m)
2025-09-30	Reported	(m)	-$17.63M	(m)	$1.75M	(m)	$91.00K*	-$12.92M*	(m)	$11.15M	(m)	(m)
2025-06-30	Reported	(m)	-$13.79M	(m)	$1.37M	(m)	$43.00K*	-$10.73M*	(m)	$8.40M	(m)	(m)
2025-03-31	Reported	(m)	-$14.50M	(m)	$1.48M	(m)	$16.00K	-$19.36M	(m)	$9.53M	(m)	(m)
2024-09-30	Reported	(m)	-$13.25M	(m)	$1.14M	(m)	$507.00K*	-$11.27M*	(m)	$8.11M	(m)	(m)
2024-06-30	Reported	(m)	-$15.45M	(m)	$1.14M	(m)	$513.00K*	-$9.91M*	(m)	$8.90M	(m)	(m)
2024-03-31	Reported	(m)	-$12.22M	(m)	$1.01M	(m)	$2.35M	-$10.60M	(m)	$6.83M	(m)	(m)
2023-09-30	Reported	(m)	-$12.43M	(m)	$3.70M	(m)	$3.37M*	-$13.71M*	(m)	(m)	(m)	(m)
2023-06-30	Reported	(m)	-$23.54M	(m)	$485.00K	(m)	$2.78M*	-$18.81M*	(m)	(m)	(m)	(m)
2023-03-31	Reported	(m)	-$18.04M	(m)	$443.00K	(m)	$1.61M	-$18.24M	(m)	(m)	(m)	(m)
2022-09-30	Reported	(m)	-$25.11M	(m)	$466.00K	(m)	$844.00K*	-$14.30M*	(m)	(m)	(m)	$0.00
2022-06-30	Reported	(m)	-$21.58M	(m)	$643.00K	(m)	$1.37M*	-$13.80M*	(m)	(m)	(m)	(m)
2022-03-31	Reported	(m)	-$19.03M	(m)	$500.00K	(m)	$223.00K	-$15.07M	(m)	(m)	(m)	(m)
2021-09-30	Reported	(m)	-$10.79M	(m)	(m)	(m)	$223.00K*	-$8.05M*	(m)	(m)	(m)	-$52.00K
2021-06-30	Reported	(m)	-$25.61M	(m)	(m)	(m)	$263.00K*	-$21.80M*	(m)	(m)	(m)	(m)
2021-03-31	Reported	(m)	-$7.06M	(m)	(m)	(m)	$261.00K	-$5.28M	(m)	(m)	(m)	(m)
2020-09-30	Reported	(m)	-$10.18M	(m)	(m)	(m)	$22.00K*	-$2.65M*	(m)	(m)	(m)	$0.00
2020-06-30	Reported	(m)	-$3.37M	(m)	(m)	(m)	-$19.00K*	-$3.09M*	(m)	(m)	(m)	(m)
2020-03-31	Reported	(m)	-$3.93M	(m)	(m)	(m)	$53.00K	-$4.69M	(m)	$1.65M	(m)	(m)
2019-09-30	Reported	(m)	-$2.71M	(m)	(m)	(m)	$0.00*	-$2.12M*	(m)	$1.31M	(m)	(m)
2019-06-30	Reported	(m)	-$2.33M	(m)	(m)	(m)	-$8.51K*	-$3.36M*	$0.00*	$1.24M	(m)	$0.00*
2019-03-31	Reported	(m)	-$4.84M	(m)	$0.00	(m)	$10.58K	-$2.67M	$900.00K	$3.79M	(m)	$0.00
2018-09-30	Reported	(m)	-$2.40M	(m)	$0.00	(m)	$793.00*	-$3.08M*	(m)	$1.56M	(m)	$0.00*
2018-06-30	Reported	(m)	-$4.05M	(m)	$0.00	(m)	-$1.18M*	-$9.05M*	(m)	$2.83M	(m)	$0.00*
2018-03-31	Reported	(m)	-$6.09M	(m)	$0.00	(m)	$1.25M	$3.29M	(m)	$3.29M	(m)	$0.00
2017-09-30	Reported	(m)	-$5.71M	(m)	$0.00	(m)	$57.00K*	-$5.73M*	(m)	$3.49M	(m)	$0.00*
2017-06-30	Reported	(m)	-$6.37M	(m)	$0.00	(m)	$38.00K*	(m)	(m)	$4.21M	(m)	$0.00*
2017-03-31	Reported	(m)	-$6.83M	(m)	(m)	(m)	$37.00K	(m)	(m)	$4.50M	(m)	$0.00
2016-09-30	Reported	(m)	-$6.65M	(m)	(m)	(m)	$3.00K*	(m)	(m)	$4.88M	(m)	(m)
2016-06-30	Reported	(m)	-$7.96M	(m)	(m)	(m)	$282.00K*	(m)	(m)	$5.79M	(m)	(m)
2016-03-31	Reported	(m)	-$7.80M	(m)	(m)	(m)	$32.00K	(m)	(m)	$5.59M	(m)	(m)
2015-09-30	Reported	(m)	-$8.04M	(m)	(m)	(m)	$498.00K*	(m)	(m)	$5.85M	(m)	(m)
2015-06-30	Reported	(m)	-$7.59M	(m)	(m)	(m)	$405.00K*	(m)	(m)	$5.86M	(m)	(m)
2015-03-31	Reported	(m)	-$7.87M	(m)	(m)	(m)	$915.00K	(m)	(m)	$5.76M	(m)	(m)
2014-09-30	Reported	(m)	-$14.94M	(m)	(m)	(m)	(m)	(m)	(m)	$13.24M	(m)	(m)
2014-06-30	Reported	(m)	-$6.01M	(m)	(m)	(m)	$73.00K*	(m)	(m)	$4.67M	(m)	(m)
2014-03-31	Reported	(m)	-$5.17M	(m)	(m)	(m)	$120.00K	(m)	(m)	-$3.37M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$62.92M	(m)	$4.41M	(m)	$185.00K	-$56.96M	(m)	$39.75M	(m)	$0.00
2024-12-31	Reported	(m)	-$54.76M	(m)	$4.05M	(m)	$3.38M	-$42.14M	(m)	$32.13M	(m)	$0.00
2023-12-31	Reported	(m)	-$65.53M	(m)	$6.04M	(m)	$10.48M	-$62.05M	(m)	$39.57M	(m)	$0.00
2022-12-31	Reported	-$88.59M	(m)	(m)	(m)	-3560.73%	$4.46M	-$60.08M	(m)	(m)	(m)	$0.00
2021-12-31	Reported	-$57.8M	(m)	(m)	(m)	(m)	$939.00K	-$47.94M	(m)	(m)	(m)	-$52.00K
2020-12-31	Reported	(m)	-$21.29M	(m)	(m)	(m)	$307.00K	-$14.71M	(m)	(m)	(m)	$0.00
2019-12-31	Reported	(m)	-$14.16M	(m)	(m)	(m)	$30.00K	-$16.89M	(m)	$8.09M	(m)	$0.00
2018-12-31	Reported	(m)	-$16.14M	(m)	$0.00	(m)	$77.41K	-$11.63M	(m)	$10.32M	(m)	(m)
2017-12-31	Reported	(m)	-$24.95M	(m)	$0.00	(m)	$276.00K	-$23.02M	(m)	$15.57M	(m)	(m)
2016-12-31	Reported	(m)	-$30.31M	(m)	(m)	(m)	$320.00K	(m)	(m)	$21.58M	(m)	(m)
2015-12-31	Reported	(m)	-$31.82M	(m)	(m)	(m)	$1.95M	(m)	(m)	$23.24M	(m)	(m)
2014-12-31	Reported	(m)	-$32.66M	(m)	(m)	(m)	$3.32M	(m)	(m)	$26.04M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Cabaletta Bio, Inc. (CABA)	United States	$0.365B	-2.81
Artiva Biotherapeutics, Inc. (ARTV)	United States	$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)	United States	$0.371B	-115.85
C4 Therapeutics, Inc. (CCCC)	United States	$0.373B	-5.65
Century Therapeutics, Inc. (IPSC)	United States	$0.306B	-4.02
SAB Biotherapeutics, Inc. (SABS)	United States	$0.306B	-25.49
AGENUS INC (AGEN)	United States	$0.383B	1.41
X4 Pharmaceuticals, Inc (XFOR)	United States	$0.297B	-4.99
Inhibikase Therapeutics, Inc. (IKT)	United States	$0.296B	-4.44
Surrozen, Inc./DE (SRZN)	United States	$0.395B